ArQule Message Board - Msg: 10787714

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule

ARQL 20.00

0.0%

Jan 16 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tommysdad who wrote (377)	8/2/1999 9:44:00 PM
From: Herc	of 399

<<Yes. But, theoretically, the new drug is better than the old drug -- why risk malpractice by prescribing an old, inferior drug? Many (most?) new drug introductions are simply improvements over existing medications.>> We doctors are increasingly being dictated what medicines we can prescribe. HMO's love generics and wait until Medicare starts paying for drugs. There are some dynamite new glaucoma drops out there, but in wholey new classes of drugs. As far as anti inflammatories and antibiotics, generics work fine. I guess what I'm saying is that I only gouge the patients with expensive drugs if they are new and clearly superior. And in my experience these are completely different classes of drugs, not just tinkering with old formulations.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next